- 中国精品科技期刊
- 中国高校百佳科技期刊
- 中国中文核心期刊
- 中国科学引文数据库核心期刊
| Citation: |
LIU Jingfeng, ZUO Chenwei, SHI Yangfan, et al. Foreign generic drug substitution policies for narrow therapeutic index drugs and their implications for China[J]. J China Pharm Univ, 2024, 55(4): 565 − 572. DOI: 10.11665/j.issn.1000-5048.2023092301
|
In order to ensure the safety and efficacy of generic drugs for the substitution of narrow therapeutic index (NTI) drugs, and to improve and optimize China's generic drug substitution policy, we searched foreign literature databases and government websites to collect and sort out the typical measures taken by some foreign countries to ensure the safety and efficacy of generic drugs for the substitution of NTI drugs, including R&D registration, generic drug substitution and post-market surveillance. On the basis of comparative analysis, this paper summarizes the practices China can learn from. It can be seen that there are problems and challenges in China's generic drug substitution for NTI drugs, such as unclear targets for bioequivalence studies of NTI drugs, insufficient rational decision-making basis for generic substitution of NTI drugs, and imperfect post-market surveillance system, etc. It is recommended that we should formulate a list of NTI drugs, play the roles of physicians and pharmacists in generic drug substitution, adjust the generic drug substitution for NTI drugs according to the level of risk of drug use, and improve the reporting system for adverse reactions due to generic drug substitution.
| [1] |
Chen ZD. Differences and safe use recommendations of narrow therapeutic index drugs[J]. Shanghai Med Pharm J(上海医药), 2019, 40(13): 29-35.
|
| [2] |
Chen XP, Hu CY, Zhang L. Common narrow therapeutic index drugs and the current status of bioequivalence evaluation[J]. Chin J Clin Pharm Ther(中国临床药理学与治疗学), 2019, 24(10): 1188-1193.
|
| [3] |
Blix HS, Viktil KK, Moger TA, et al. Drugs with narrow therapeutic index as indicators in the risk management of hospitalised patients[J]. Pharm Pract (Granada), 2010, 8(1): 50-55.
|
| [4] |
Kwon M, Yeom D, Kim NA, et al. Bioequivalence of tacrolimus formulations with different dynamic solubility and in-vitro dissolution profiles[J]. Arch Pharm Res, 2015, 38(1): 73-80. doi: 10.1007/s12272-014-0343-3
|
| [5] |
Liow K, Barkley G L, Pollard J R, et al. Position statement on the coverage of anticonvulsant drugs for the treatment of epilepsy[J]. Neurology, 2007, 68(16): 1249-1250. doi: 10.1212/01.wnl.0000259400.30539.cc
|
| [6] |
Ting TY, Jiang W, Lionberger R, et al. Generic lamotrigine versus brand‐name Lamictal bioequivalence in patients with epilepsy: a field test of the FDA bioequivalence standard[J]. Epilepsia, 2015, 56(9): 1415-1424. doi: 10.1111/epi.13095
|
| [7] |
Privitera MD, Welty TE, Gidal BE, et al. Generic-to-generic lamotrigine switches in people with epilepsy: the randomised controlled EQUIGEN trial[J]. Lancet Neurol, 2016, 15(4): 365-372. doi: 10.1016/S1474-4422(16)00014-4
|
| [8] |
He RR, Li L, Yang JB. FDA introduction to in vitro andin vivo bioequivalence studies of inhaled powder aerosol[J]. Chin Food Drug Administ Magaz (中国食品药品监管), 2019(6): 22-29.
|
| [9] |
Ju GH, Liu X, Wang XT, et al. Introduction of the evaluation methods for bioequivalence studies[J]. Chin J Clin Pharmacol (中国临床药理学杂志), 2022, 38(22): 2771-2775.
|
| [10] |
Liu D, Han HC, Wang J. Consideration of in vivo bioequivalence research for narrow therapeutic index drugs[J]. Drug Eval Res(药物评价研究), 2021, 44(10): 2262-2267.
|
| [11] |
Lamotrigine[J]. Shanghai Med Pharm J(上海医药), 2020, 41 (S2): 48-50.
|
| [12] |
REN XY, Yan JZ, Ding RL, et al. Experience and enlightenment of generic drug substitution promotion policy in drug use in typical foreign countries[J]. Chin J Health Pol(中国卫生政策研究), 2023, 16(12): 49-55.
|
| [13] |
Liow K, Barkley GL, Pollard JR, et al. Position statement on the coverage of anticonvulsant drugs for the treatment of epilepsy[J]. Neurology, 2007, 68(16): 1249-1250. doi: 10.1212/01.wnl.0000259400.30539.cc
|
| [14] |
American Epilepsy Society. The substitution of different formulations of antiepileptic drugs for the treatment of epilepsy [EB/OL]. (2020-12-30)[2022-06-06]. https://aesnet.org/about/about-aes/position-statements/substitution-of-different-formulations-of-antiepileptic-drugs-for-the-treatment-of-epilepsy?_gl=1*oq0mua*_ga*NTA3ODE5MTk4LjE2OTQ1MTExNjE.*_ga_GV192D9FPY*MTY5NDUxMTE2MC4xLjEuMTY5NDUxMTI1OS40Ny4wLjA.
|
| [15] |
Epilepsy Foundation. ACCESS TO PRESCRIPTION MEDICATIONS[EB/OL]. (2022-03-31)[2022-06-06] https://epilepsyode3.prod.acquiasites.com/sites/default/files/atoms/files/Access%20to%20Prescription%20Medications%20Position%20Paper.pdf.
|
| [16] |
NICE. Epilepsies in children, young people and adults[EB/OL]. (2022-04-27)[2023-01-01]. https://www.nice.org.uk/guidance/ng217/chapter/4-Principles-of-treatment-safety-monitoring-and-withdrawal.
|
| [17] |
The UK warns of the potential risks of switching between different anti-epileptic drugs[J]. J China Rx Drug(中国处方药), 2014, 12 (1): 128.
|
| [18] |
Carswell JM, Gordon JH, Popovsky E, et al. Generic and brand-name L-thyroxine are not bioequivalent for children with severe congenital hypothyroidism[J]. J Clin Endocrinol Metab, 2013, 98(2): 610-617. doi: 10.1210/jc.2012-3125
|
| [19] |
FDA. Product-specific recommendations for generic drug development[EB/OL]. (2022-11-21)[2023-01-01]. https://www.fda.gov/drugs/guidances-drugs/product-specific-guidances-generic-drug-development.
|
| [20] |
Food and drug administration, FDA. Setting and Implementing Standards for Narrow Therapeutic Index Drugs[EB/OL]. (2024-02-26)[2024-03-28]. https://www.fda.gov/drugs/cder-conversations/setting-and-implementing-standards-narrow-therapeutic-index-drugs.
|
| [21] |
Center for Drug Evaluation, NMPA. Questions and Answers on the "Prescription proportion Similarity" of multi-specification exemption BE pharmaceutical evaluation standard in China's "Technical Guidelines for Human Bioequivalence Studies of Chemical Generic Drugs with Pharmacokinetic Parameters as the End Point Evaluation Index" (Trial). [EB/OL](2022-02-10)[2023-01-01]. https://www.cde.org.cn/zdyz/domesticinfopa-ge?zdyzIdCODE=e3835d476d956df4b8a2bf543daf277f.
|
| [22] |
Center for Drug Evaluation, NMPA. Notice of the Drug Evaluation Center of NMPA on the Release of the "Technical Guidelines for Bioequivalence Research of Narrow Therapeutic Index Drugs" (No. 62 of 2020). [EB/OL](2020-12-31)[2023-03-28]. https://www.cde.org.cn/main/news/viewInfoCommon/cad15062ff21d6f5b164fa9c562a709e.
|
| [23] |
Yan JZ, Li DS, Ding WJ, et al. A comparative study on the promotion policies of generic drug substitution between China, the United States and Japan based on full cycle management[J]. Chin J Hlth Pol(中国卫生政策研究), 2023, 16(4): 37-43.
|
| [24] |
Li LG, Gucicely. Monitoring and assessment of hospital adverse drug reactions in domestic and foreign countries[J]. Chin Rur Hlth Svs Admin (中国农村卫生事业管理), 2010, 30(5): 333-335.
|
| [25] |
Health Canada. Guidance Document - Comparative Bioavailability Standards: Formulations Used for Systemic Effects[EB/OL]. (2018-06-08)[2023-01-01]. https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/bioavailability-bioequivalence/comparative-bioavailability-standards-formulations-used-systemic-effects.html.
|
| [26] |
Wang CC, Lu MQ, Xu AL, et al. The enlightenment of French generic drugs substitution plan to China[J]. Chin New Drugs J(中国新药杂志), 2020, 29(8): 869-874.
|
| [27] |
Saedder EA, Brock B, Nielsen LP, et al. Classification of drugs with different risk profiles[J]. Dan Med J, 2015, 62(8): 1-6.
|
| [28] |
Maaskant JM, Eskes A, van Rijn-Bikker P, et al. High-alert medications for pediatric patients: an international modified Delphi study[J]. Expert Opin Drug Saf, 2013, 12(6): 805-814. doi: 10.1517/14740338.2013.825247
|
| [29] |
Xiao SW, Zhu XL, Gao LN, et al. Signal mining of adverse drug events of tofacitinib based on FAERS datebase[J]. Drugs Clin (现代药物与临床), 2022, 37(11): 2628-2634.
|
Supported by: Beijing Renhe Information Technology Co., Ltd. 
Total visits：292830
DownLoad: